TACTIC  Publications

  1. Galvez BPJ, Woelffing P, Schwarz M, Ebner S, Rudalska R, Masberg B, Esposito A, Rashidian A, Schevchenko E, Smutna L, Pavek P, Kublbeck J, Kronenberger T, Zender L, Lammerhofer M, Dauch D, and Laufer SA (2025). Uncovering alpha-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies. J Med Chem 68: 7180-7196.PubMed
  2. Edmonds AK, Balourdas DI, Marsh GP, Felix R, Brasher B, Cooper J, Graber-Feesl C, Kollareddy M, Malik K, Stewart H, Chevassut TJT, Lineham E, Morley S, Fedorov O, Bennett J, Rajasekaran MB, Ojeda S, Harrison DA, Ott CJ, Joerger AC, Maple HJ, and Spencer J (2025). Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse. J Med Chem 68: 9638-9660.PubMed
  3. Wagner K, Keiten-Schmitz J, Adhikari B, Patra U, Husnjak K, McNicoll F, Dormann D, Muller-McNicoll M, Tascher G, Wolf E, and Muller S (2025). Induced proximity to PML protects TDP-43 from aggregation via SUMO-ubiquitin networks. Nat Chem Biol.PubMed
  4. Zhao B, Fang R, Schurmann H, Hemmer EJ, Mayer GL, Trajkovic-Arsic M, Althoff K, Yang J, Godfrey L, Liffers ST, Savvatakis K, Dorsch M, Gruner BM, Hahn S, Remke M, Lueong SS, and Siveke JT (2025). PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell Rep 44: 115541.PubMed
  5. Maciel EVS, Eisert J, Dederer V, Berwanger A, Knapp S, Empting M, Mathea S, Jensen H, and Lermyte F (2025). Native Flow-Induced Dispersion Analysis - Mass Spectrometry Enables Automated, Multiplexed Ligand Screening from Conventional, Nonvolatile Buffers. Anal Chem.PubMed
  6. Muller S, Sanfelice D, and Workman P (2025). Probing cancer with small-molecule tools-Progress and challenges. Cancer Cell 43: 323-327.PubMed
  7. Willems S, Maksumic L, Niggenaber J, Lin TC, Schulz T, Weisner J, Sievers S, Muller MP, Summerer D, and Rauh D (2025). Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation. ACS Med Chem Lett 16: 804-810.PubMed
  8. Eisert J, Maciel EVS, Dederer V, Berwanger A, Bailey HJ, Dikic I, Knapp S, Empting M, Mathea S, Jensen H, and Lermyte F (2025). Native Taylor/Non-Taylor Dispersion-Mass Spectrometry (TNT-MS) Allows Rapid Protein Desalting and Multiplexed, Label-Free Ligand Screening. Small Methods: e2500658.PubMed
  9. Mandel S, Hanke T, Mathea S, Chatterjee D, Saraswati H, Berger BT, Schwalm MP, Yamamoto S, Tawada M, Takagi T, Ahmed M, Rohm S, Corrionero A, Alfonso P, Baena M, Elson L, Menge A, Kramer A, Pereira R, Muller S, Krause DS, and Knapp S (2025). Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor. ACS Chem Biol.PubMed
  10. Wang X, Sun J, Ahmad S, Yang D, Li F, Chan UH, Zeng H, Simoben CV, Houliston S, Dong A, Bolotokova A, Gibson E, Kutera M, Ghiabi P, Kondratov I, Matviyuk T, Chuprina A, Mavridi D, Lenz C, Joerger AC, Brown BD, Heath RB, Yue WW, Robbie LK, Beyett TS, Muller S, Knapp S, Harding R, Schapira M, Brown PJ, Santhakumar V, Ackloo S, Arrowsmith CH, Edwards AM, Peng H, and Halabelian L (2025). Enantioselective Protein Affinity Selection Mass Spectrometry (EAS-MS). bioRxiv.PUbMed
  11. Funk JS, Klimovich M, Drangenstein D, Pielhoop O, Hunold P, Borowek A, Noeparast M, Pavlakis E, Neumann M, Balourdas DI, Kochhan K, Merle N, Bullwinkel I, Wanzel M, Elmshauser S, Teply-Szymanski J, Nist A, Procida T, Bartkuhn M, Humpert K, Mernberger M, Savai R, Soussi T, Joerger AC, and Stiewe T (2025). Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. Nat Genet 57: 140-153.PubMed
  12. Bhandare P, Narain A, Hofstetter J, Rummel T, Wenzel J, Schulein-Volk C, Lamer S, Eilers U, Schlosser A, Eilers M, Erhard F, and Wolf E (2025). Phenotypic screens identify SCAF1 as critical activator of RNAPII elongation and global transcription. Nucleic Acids Res 53.PubMed
  13. Schulz T, Gontla R, Teuber A, Beerbaum M, Fletcher BS, Muhlenberg T, Kaitsiotou H, Hardick J, Jeyakumar K, Keul M, Muller MP, Sievers S, Bauer S, and Rauh D (2025). Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors horizontal line Exploring Their Potential in Targeting GIST. J Med Chem 68: 3238-3259.PubMed
  14. Moyano PM, Kubina T, Paruch SO, Jaroskova A, Novotny J, Skockova V, Ovesna P, Suchankova T, Prokofeva P, Kuster B, Smida M, Chaikuad A, Kramer A, Knapp S, Soucek K, and Paruch K (2025). Thieno[3,2-b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode. Angew Chem Int Ed Engl 64: e202412786.PubMed
  15. Miletic N, Weckesser J, Mosler T, Rathore R, Hoffmann ME, Gehrtz P, Schlesiger S, Hartung IV, Berner N, Wilhelm S, Muller J, Adhikari B, Nemec V, Sivashanmugam SA, Elson L, Holzmann H, Schwalm MP, Hoffmann L, Abdul Azeez KR, Muller S, Kuster B, Wolf E, Dikic I, and Knapp S (2025). Workflow for E3 Ligase Ligand Validation for PROTAC Development. ACS Chem Biol 20: 507-521.PubMed
  16. Haag A, Nemec V, Janovska P, Bartosikova J, Adhikari B, Muller J, Schwalm MP, Cada S, Ohmayer U, Daub H, Kim Y, Born F, Wolf E, Bryja V, and Knapp S (2025). Development and Discovery of a Selective Degrader of Casein Kinases 1 delta/epsilon. J Med Chem 68: 506-530.PubMed
  17. Pieper NM, Schnell J, Bruecher D, Knapp S, and Vogler M (2024). Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFkappaB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell Commun Signal 22: 415.PubMed
  18. Zhu WF, Franz HM, Kramer A, Duman E, Empel C, Gobel MW, Koenigs RM, Knapp S, Hiesinger K, Proschak E, and Hernandez-Olmos V (2024). Oxadiazolone-Based Aromatic Annulations: A Nitrenoid Precursor for Tricyclic Aminoheterocycles. J Org Chem 89: 15542-15552.PubMed
  19. Vogt M, Dudvarski Stankovic N, Cruz Garcia Y, Hofstetter J, Schneider K, Kuybu F, Hauck T, Adhikari B, Hamann A, Rocca Y, Grysczyk L, Martin B, Gebhardt-Wolf A, Wiegering A, Diefenbacher M, Gasteiger G, Knapp S, Saur D, Eilers M, Rosenfeldt M, Erhard F, Vos SM, and Wolf E (2024). Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. Gut 73: 1509-1528.PubMed
  20. Kramer A and Knapp S (2024). Elimination of mutant SWI/SNF complexes by protein quality control: new opportunities targeting aggressive rhabdoid tumours. Signal Transduct Target Ther 9: 224.PubMed
  21. Sflakidou E, Adhikari B, Siokatas C, Wolf E, and Sarli V (2024). Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases. ACS Pharmacol Transl Sci 7: 3488-3501.PubMed